- Home
- CBLL vs FULC Comparison
CBLL vs FULC Comparison
Compare CBLL & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBLL
- FULC
- Stock Information
- Founded
- CBLL 2014
- FULC 2015
- Country
- CBLL United States
- FULC United States
- Employees
- CBLL N/A
- FULC N/A
- Industry
- CBLL
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- CBLL
- FULC Health Care
- Exchange
- CBLL Nasdaq
- FULC Nasdaq
- Market Cap
- CBLL 433.7M
- FULC 469.0M
- IPO Year
- CBLL 2024
- FULC 2019
- Fundamental
- Price
- CBLL $12.88
- FULC $9.15
- Analyst Decision
- CBLL Strong Buy
- FULC Buy
- Analyst Count
- CBLL 7
- FULC 7
- Target Price
- CBLL $30.67
- FULC $9.14
- AVG Volume (30 Days)
- CBLL 258.5K
- FULC 441.0K
- Earning Date
- CBLL 11-04-2025
- FULC 10-29-2025
- Dividend Yield
- CBLL N/A
- FULC N/A
- EPS Growth
- CBLL N/A
- FULC N/A
- EPS
- CBLL N/A
- FULC N/A
- Revenue
- CBLL $77,419,000.00
- FULC N/A
- Revenue This Year
- CBLL $35.45
- FULC N/A
- Revenue Next Year
- CBLL $28.18
- FULC N/A
- P/E Ratio
- CBLL N/A
- FULC N/A
- Revenue Growth
- CBLL 42.16
- FULC 2752.05
- 52 Week Low
- CBLL $10.01
- FULC $2.32
- 52 Week High
- CBLL $32.75
- FULC $9.89
- Technical
- Relative Strength Index (RSI)
- CBLL 54.34
- FULC 54.35
- Support Level
- CBLL $12.54
- FULC $8.89
- Resistance Level
- CBLL $13.86
- FULC $9.84
- Average True Range (ATR)
- CBLL 0.67
- FULC 0.58
- MACD
- CBLL 0.09
- FULC -0.09
- Stochastic Oscillator
- CBLL 58.52
- FULC 47.57
About CBLL CeriBell Inc.
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.